Which one is better, opicapone or rasagiline?

Opicapone and Rasagiline are both drugs used to treat Parkinson's disease, but they have different mechanisms of action and effects and may be suitable for patients at different stages. Which drug is more effective should be determined based on the patient's condition, doctor's advice and individual differences. Do not use drugs arbitrarily. If you are being treated for Parkinson's disease, be sure to talk to your doctor.

Opicapone is a catechol-O-methyltransferase (COMT) inhibitor. The main component is opicapone. It increases the concentration of dopamine in the nervous system by reducing the rate of dopamine degradation in patients with Parkinson's disease. This medication may be used with other Parkinson's disease medications (such as levodopa and carbidopa) to help control motor symptoms and prolong the effects of dopamine medications. Rasagiline is a selective monoamine oxidase-B (MAO-B) inhibitor whose main component is rasagiline. It inhibits the activity of MAO-B enzyme and increases the concentration of dopamine in the brain, thereby alleviating the symptoms of Parkinson's disease. Rasagiline is usually used as a stand-alone medication to treat early-stage Parkinson's disease.

Opicapone has not yet been launched in the country, so it is not covered by medical insurance. The European version of Opicapone’s original drug specifications listed overseasThe price per box of 50mg*90 capsules is around RMB 6,000 (the price may fluctuate due to the exchange rate). There is currently no generic version of Opicapone on the market. For more drug information and specific prices, please consult Yaode’s medical consultant.